ArticleGeburtshilfe und Frauenheilkunde2026
RSV Prophylaxis in Neonates: Implementation and Parental Acceptance during the First RSV Season in Germany.
Article in Geburtshilfe und Frauenheilkunde, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: RSV is the leading cause of lower respiratory tract infections (LRTI) in infants. Since 2024, STIKO recommends immunising all neonates with nirsevimab prior to or during their first RSV season. This study aims to assess parental acceptance and uptake of RSV immunisation during the first implementation season in Germany. Methods: All neonates born at our hospital between 11 November 2024 and 31 January 2025 were included in this study. Parents received an antenatal information leaflet; counselling was part of the U2 medical checkup. The immunisation rate was assessed using data from electronic medical records. In addition, an online questionnaire surveyed parental satisfaction with the information provided. Results: Of 1030 neonates, 76% received nirsevimab, 6% were protected by maternal RSVpreF vaccination (overall immunisation rate: 82%). Children of multiparous mothers were immunised less often than children of primiparous mothers (OR = 0.52; p < 0.001). Mothers aged ≥ 30 years were more likely to consent to vaccination (30-34: OR = 1.75; ≥ 35: OR = 1.72). 68% of parents had already made their decision prior to delivery. Of 153 respondents, 17% requested more detailed information on safety, duration of vaccination protection, and availability of the vaccine. Conclusion: Maternal age and parity appear to be associated with nirsevimab uptake. Early prepartum counselling and transparent communications regarding product safety could further increase acceptance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.